New antibody drug aims to block brain attacks in autoimmune encephalitis

NCT ID NCT06575153

Completed Disease control Sponsor: Arialys Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new drug called ART5803 in 64 healthy adults to see if it is safe. ART5803 is a lab-made antibody designed to block harmful immune proteins that attack the brain in autoimmune encephalitis. The study gave single or multiple doses and compared them to a placebo, focusing on safety and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ART5803 (a lab-made antibody that blocks harmful immune attacks on brain cells)
What this could lead to: If safe, this could lead to a treatment that stops the immune system from attacking the brain in autoimmune encephalitis, potentially controlling the disease.
What could go wrong: This is an early Phase 1 safety study in only 64 healthy people, not patients. It does not test if the drug works for the disease, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE ENCEPHALITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disorder of the nervous system autoimmune encephalitis encephalitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE ENCEPHALITIS

Contacts and locations

Locations

Nucleus Network Pty Ltd

Melbourne, Victoria, 3004, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.